Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ehc (european health corporation) sa - säure-salicylicum, malvae folii mucilago, althaeae folii mucilago, menthae piperitae aetheroleum - émulsion buccale - acidum salicylicum 4 mg, malvae folii mucilago 335 mg, althaeae folii mucilago 335 mg, menthae piperitae aetheroleum 4.5 mg, saccharum et aqua purificata, ammonii hydrogenocitras, acaciae gummi, paraffinum liquidum, saccharinum natricum, vanillinum, rosmarini aetheroleum, salviae aetheroleum, ad emulsionem pro 1 g corresp. limonenum 0.113 mg. - erkrankungen der kehle und mund - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ehc (european health corporation) sa - faex medicinalis siccata, carbo activatus - gélules pour adultes - faex medizinische siccata 108.5 mg carbo activatus 109 mg, color.: e 127, excipiens für die kapsel. - diarrhée aiguë, normalisation de la flore intestinale, troubles intestinaux après la prise d'antibiotiques - bakterien- und hefepräparate

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ehc (european health corporation) sa - faex medicinalis siccata, carbo activatus - gélules pour enfants - faex medizinische siccata 47.7 mg carbo activatus 48 mg, color.: e 127, excipiens für die kapsel. - diarrhée aiguë, normalisation de la flore intestinale, troubles intestinaux après la prise d'antibiotiques - bakterien- und hefepräparate

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ehc (european health corporation) sa - magnesium - - beutel, pulver - magnesium-l-pidolas hydricus 1,5 g endwerte. magnesium 122 mg, zucker, saccharinum natricum, excipiens pulver für das papier. - mängel magnésiques - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ehc (european health corporation) sa - magnesium - - beutel, pulver - magnesium-l-pidolas hydricus 2.25 g endwerte. magnesium 184 mg, zucker, saccharinum natricum, excipiens pulver für das papier. - mängel magnésiques - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

ehc (european health corporation) sa - lidocainum - spray - lidocainum 95 mg, sind, conserv.: propylis parahydroxybenzoas, e 218, excipiens ad-lösung für 1 g lösung 5 g und propellentia zu aerosolum 8.5 g für behälter, dosen für die behälter 180. - ejaculatio praecox - synthetika

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ge healthcare - tauroselcholic acid (se-75) - hartkapsel - 370 kbq - tauroselcholic acid (se-75) 370 kbq - selenium (75se) tauroselcholic acid

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ge healthcare buchler gmbh & co.kg (3022870) - tauroselcholsäure((75)se) - hartkapsel - tauroselcholsäure((75)se) (22660) 370000 becquerel

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

"ucb gmbh" - diphenhydraminhydrochlorid - dragees - diphenhydraminhydrochlorid 25.mg

Europäische Union - Deutsch - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantatabstoßung - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.